Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
著者
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

連絡先

Jones, Jaime L.M.
パートナー
Pirozzolo, Jack W.
パートナー

関連公式ブログ

得意分野

Suggested News & Insights

False Claims Act Risk on the RadarTuesday, October 6, 2026
Events
Eleventh Circuit Rejects Appointments Clause Challenge to Qui Tam MechanismSeptember 2, 2026
Original Source
New York Ethics Opinion Warns Lawyers on Qui Tam DeceptionSeptember 2, 2026
Law360
DOJ Continues Medicare Advantage Enforcement Focus with $541.5 Million SettlementAugust 31, 2026
Original Source
DOJ Announces Second Settlement Resolving FCA Allegations Based on Employment DiscriminationAugust 28, 2026
Original Source
Second Circuit Clarifies Scope of “Property” that an FCA “Claim” May SeekAugust 17, 2026
Original Source